AMGEN & AZ BRODALUMAB PHASE III RESULTS

AMGEN AND ASTRAZENECA ANNOUNCE POSITIVE RESULTS FROM PHASE III STUDY OF
BRODALUMAB

(AMG 827) IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS

Study evaluating novel investigational IL-17 receptor antibody

meets all primary and secondary endpoints

AstraZeneca and Amgen today announced that the Phase III AMAGINE-1TMstudy
evaluating brodalumab in patients with moderate-to-severe plaque psoriasis met
all primary and secondary endpoints for both evaluated doses. Brodalumab is the
only investigational treatment in development that binds to the interleukin-17
(IL-17) receptor and inhibits inflammatory signaling by blocking the binding of
several IL-17 ligands to the receptor. Primary endpoints were patients achieving
at least a 75 percent improvement from baseline in disease severity at week 12,
as measured by the Psoriasis Area Severity Index (PASI 75), and patients
achieving clear or almost clear skin at week 12 according to the static
Physician Global Assessment (sPGA 0 or 1).

A significantly higher proportion of patients treated with brodalumab achieved a
PASI 75 response (primary endpoint), as well as PASI 90 and PASI 100 responses
at week 12 (secondary endpoints) compared to placebo. Results showed that 83.3
percent of patients in the 210 mg group and 60.3 percent of patients in the 140
mg group achieved PASI 75 responses compared to placebo (2.7 percent). Results
also showed that 70.3 percent of patients in the 210 mg group and 42.5 percent
of patients in the 140 mg group achieved PASI 90 responses compared to placebo
(0.9 percent). Further, 41.9 percent of patients in the 210 mg group and 23.3
percent of patients in the 140 mg group achieved PASI 100 responses compared to
placebo (0.5 percent). Of the 661 patients enrolled in this study, 46 percent
reported prior biologic use and 28.7 percent weighed more than 100 kilograms
(kg) at baseline (mean weight for the study population was 90.8 kg).

A PASI score is a measure of psoriatic plaque redness, scaling and thickness and
the extent of involvement in each region of the body. Treatment efficacy is
often measured by the reduction of PASI from baseline (i.e., a 75 percent
reduction is known as PASI 75, a 90 percent reduction is known as PASI 90 and
PASI 100 is total clearance of skin disease).

The most common adverse events that occurred during the placebo-controlled
period in the brodalumab group (more than 5 percent of participants) were
nasopharyngitis, upper respiratory tract infection and headache. Serious adverse
events occurred in 1.8 percent of patients in the 210 mg group and 2.7 percent
of patients in the 140 mg group compared to 1.4 percent for placebo during the
placebo-controlled period.

“Data from the AMAGINE-1 study suggest that brodalumab may offer a new level of
efficacy for patients with moderate-to-severe plaque psoriasis, a disease that
affects more than 100 million people globally,” said Sean E. Harper, executive
vice president of Research and Development at Amgen. “This is the first read-out
from our Phase III psoriasis clinical programme and we look forward to obtaining
additional Phase III data from our two head-to-head studies versus ustekinumab
later this year.”

Psoriasis is a non-contagious chronic disease in which the immune system causes
skin cells to grow at an accelerated rate. Instead of being shed, skin cells
pile up, causing painful and itchy, red, scaly patches.

“Moderate-to-severe plaque psoriasis is a serious disease, and despite available
treatments, there is still a significant need for more effective therapies,”
said Briggs Morrison, executive vice president of Global Medicines Development
at AstraZeneca. “We are encouraged by brodalumab’s emerging profile and look
forward to presenting the full data in the appropriate scientific forum.”

AMAGINE-1 is one of three Phase III studies designed to assess the efficacy and
safety of brodalumab in patients with moderate-to-severe plaque psoriasis.
AMAGINE-2 and AMAGINE-3 are designed to evaluate the efficacy and safety of
induction and maintenance regimens of brodalumab at different dose schedules in
patients with moderate-to-severe plaque psoriasis compared to ustekinumab and
placebo.

 AMAGINE-1 Study Design

AMAGINE-1 assessed the safety and efficacy of brodalumab given every two weeks
via subcutaneous injection at two doses (140 mg or 210 mg) compared to placebo
in patients with moderate-to-severe plaque psoriasis. Another purpose of the
study was to assess safety and efficacy when patients treated with brodalumab,
who responded to treatment, began receiving placebo compared to the patients who
continued receiving brodalumab.

The Phase III study began with a 12-week, double-blind, placebo-controlled
induction phase. During this phase, patients were randomised in a 1:1:1 ratio to
receive 210 mg of brodalumab, 140 mg of brodalumab or placebo every two weeks.

At week 12, patients originally randomised to receive treatment with brodalumab
who achieved clear or almost clear skin according to their sPGA (0 or 1) were
rerandomised 1:1 to receive placebo or continued treatment with brodalumab at
the current dose. Rerandomised patients losing disease control were treated with
their original brodalumab dose. All patients originally randomised to placebo
and any patient not qualifying for rerandomisation (sPGA > 1) received 210 mg of
brodalumab every two weeks.

sPGA is a physician’s rating of psoriasis severity at a given point in time
based on plaque, scaling and redness. A physician can rate a patient’s psoriasis
as clear (0), almost clear (1), mild (2), moderate (3), severe (4) or very
severe (5).

About Brodalumab (AMG 827)

Brodalumab is a novel human monoclonal antibody that binds to the interleukin-17
(IL-17) receptor and inhibits inflammatory signaling by blocking the binding of
several IL-17 ligands to the receptor. By stopping IL-17 ligands from activating
the receptor, brodalumab prevents the body from receiving signals that may lead
to inflammation. The IL-17 pathway plays a central role in inducing and
promoting inflammatory disease processes. In addition to moderate-to-severe
plaque psoriasis (Phase III), brodalumab is currently being investigated for the
treatment of psoriatic arthritis (Phase III) and asthma (Phase II).

About the Amgen and AstraZeneca Collaboration

In April 2012, Amgen and AstraZeneca formed a collaboration to jointly develop
and commercialise five monoclonal antibodies from Amgen’s clinical inflammation
portfolio. With oversight from joint governing bodies, Amgen leads clinical
development and commercialisation for brodalumab (Phase III for moderate-to
-severe plaque psoriasis and psoriatic arthritis, Phase II for asthma) and AMG
557/MEDI5872 (Phase Ib for autoimmune diseases such as systemic lupus
erythematosus). AstraZeneca, through its biologics arm MedImmune, leads clinical
development and commercialisation for MEDI7183/AMG 181 (Phase II for ulcerative
colitis and Crohn's disease), MEDI2070/AMG 139 (Phase II for Crohn’s disease)
and MEDI9929/AMG 157 (Phase II for asthma).

About Amgen

Amgen is committed to unlocking the potential of biology for patients suffering
from serious illnesses by discovering, developing, manufacturing and delivering
innovative human therapeutics. This approach begins by using tools like advanced
human genetics to unravel the complexities of disease and understand the
fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its biologics
manufacturing expertise to strive for solutions that improve health outcomes and
dramatically improve people's lives. A biotechnology pioneer since
1980, Amgen has grown to be the world's largest independent biotechnology
company, has reached millions of patients around the world and is developing a
pipeline of medicines with breakaway potential.

For more information, visit www.amgen.com and follow us
on www.twitter.com/amgen.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that
focuses on the discovery, development and commercialisation of prescription
medicines, primarily for the treatment of cardiovascular, metabolic,
respiratory, inflammation, autoimmune, oncology, infection and neuroscience
diseases. AstraZeneca operates in over 100 countries and its innovative
medicines are used by millions of patients worldwide. For more information
please visit: www.astrazeneca.com

CONTACTS

Media Enquiries

Esra Erkal-Paler                         +44 20 7604 8030 (UK/Global)

Vanessa Rhodes                        +44 20 7604 8037 (UK/Global)

Ayesha Bharmal                         +44 20 7604 8034 (UK/Global)

Michele Meixell                           +1 302 885 2677 (US)

Jacob Lund                                 +46 8 553 260 20 (Sweden)

Investor Enquiries

Karl Hård                                    +44 20 7604 8123         mob: +44
7789 654364

Colleen Proctor                           +1 302 886 1842           mob: +1 302
357 4882

Anthony Brown                           +44 20 7604 8067         mob: +44 7585
404943

Jens Lindberg                             +44 20 7604 8414         mob: +44 7557
319729

Amgen Enquiries

Kristen Davis (media)                +1 805-447-3008

Arvind Sood (investors)             +1 805-447-1060

Forward-Looking Statements

This news release contains forward-looking statements that are based on the
current expectations and beliefs of Amgen Inc. and its subsidiaries (Amgen) and
are subject to a number of risks, uncertainties and assumptions that could cause
actual results to differ materially from those described.  All statements, other
than statements of historical fact, are statements that could be deemed forward
-looking statements, including estimates of revenues, operating margins, capital
expenditures, cash, other financial metrics, expected legal, arbitration,
political, regulatory or clinical results or practices, customer and prescriber
patterns or practices, reimbursement activities and outcomes and other such
estimates and results.  Forward-looking statements involve significant risks and
uncertainties, including those discussed below and more fully described in the
Securities and Exchange Commission (SEC) reports filed by Amgen Inc., including
Amgen Inc.’s most recent annual report on Form 10-K and any subsequent periodic
reports on Form 10-Q and Form 8-K.  Please refer to Amgen Inc.’s most recent
Forms 10-K, 10-Q and 8-K for additional information on the uncertainties and
risk factors related to Amgen’s business.  Unless otherwise noted, Amgen is
providing this information as of May 9, 2014 and expressly disclaims any duty to
update information contained in this news release.

No forward-looking statement can be guaranteed and actual results may differ
materially from those Amgen projects. Discovery or identification of new product
candidates or development of new indications for existing products cannot be
guaranteed and movement from concept to product is uncertain; consequently,
there can be no guarantee that any particular product candidate or development
of a new indication for an existing product will be successful and become a
commercial product. Further, preclinical results do not guarantee safe and
effective performance of product candidates in humans. The complexity of the
human body cannot be perfectly, or sometimes, even adequately modeled by
computer or cell culture systems or animal models. The length of time that it
takes for Amgen and its partners to complete clinical trials and obtain
regulatory approval for product marketing has in the past varied and Amgen
expects similar variability in the future. Amgen develops product candidates
internally and through licensing collaborations, partnerships and joint
ventures.   Product candidates that are derived from relationships may be
subject to disputes between the parties or may prove to be not as effective or
as safe as Amgen may have believed at the time of entering into such
relationship. Also, Amgen or others could identify safety, side effects or
manufacturing problems with Amgen’s products after they are on the market.
Amgen’s business may be impacted by government investigations, litigation and
product liability claims. If Amgen fails to meet the compliance obligations in
the corporate integrity agreement between Amgen and the U.S. government, Amgen
could become subject to significant sanctions. Amgen depends on third parties
for a significant portion of its manufacturing capacity for the supply of
certain of its current and future products and limits on supply may constrain
sales of certain of its current products and product candidate development.

In addition, sales of Amgen’s products (including products of Amgen’s wholly
-owned subsidiaries) are affected by the reimbursement policies imposed by third
-party payers, including governments, private insurance plans and managed care
providers and may be affected by regulatory, clinical and guideline developments
and domestic and international trends toward managed care and healthcare cost
containment as well as U.S. legislation affecting pharmaceutical pricing and
reimbursement. Government and others’ regulations and reimbursement policies may
affect the development, usage and pricing of Amgen’s products. In addition,
Amgen competes with other companies with respect to some of its marketed
products as well as for the discovery and development of new products. Amgen
believes that some of its newer products, product candidates or new indications
for existing products, may face competition when and as they are approved and
marketed. Amgen’s products may compete against products that have lower prices,
established reimbursement, superior performance, are easier to administer, or
that are otherwise competitive with its products. In addition, while Amgen and
its partners routinely obtain patents for their products and technology, the
protection of Amgen’s products offered by patents and patent applications may be
challenged, invalidated or circumvented by its competitors and there can be no
guarantee of Amgen’s or its partners’ ability to obtain or maintain patent
protection for Amgen’s products or product candidates. Amgen cannot guarantee
that it will be able to produce commercially successful products or maintain the
commercial success of its existing products. Amgen’s stock price may be affected
by actual or perceived market opportunity, competitive position, and success or
failure of its products or product candidates. Further, the discovery of
significant problems with a product similar to one of Amgen’s products that
implicate an entire class of products could have a material adverse effect on
sales of the affected products and on Amgen’s business and results of
operations. Amgen’s efforts to integrate the operations of companies it has
acquired may not be successful.

The scientific information discussed in this news release relating to our
product candidates is preliminary and investigative. Such product candidates are
not approved by the U.S. Food and Drug Administration (FDA) , and no conclusions
can or should be drawn regarding the safety or effectiveness of the product
candidates.

12 May 2014

-ENDS-